Gallant 1971.

Methods	Allocation: randomised by random numbers. Blinding: double blind. Duration: 8 weeks, with 4 weeks washout.
Participants	Diagnosis: chronic schizophrenia. N=24. Age: range 30‐55. Sex: 11 M, 13F. Design: phase 2 trial.
Interventions	1. Loxapine: dose 20 mg/day increased to 120 mg/day. N=12. 2. Trifluperazine: dose 10 mg/day increased up to 60 mg/day. N=12. Antiparkinsonian medication given as required.
Outcomes	Adverse events. Unable to use ‐ Global effect: CGI (no data). Mental state: BPRS (no data). Behaviour: NOSIE (no data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear